Background and objective Monitoring renal function is critical in treating pediatric patients, especially when dosing nephrotoxic agents. We evaluated the validity of the bedside Schwartz and Brandt equations in pediatric oncology patients and developed new equations for estimated glomerular filtration rate (eGFR) in these patients. Methods A retrospective analysis was conducted comparing eGFR using the bedside Schwartz and Brandt equations to measured GFR (mGFR) from technetium-99m diethylenetriamine pentaacetic acid ( Tc-DTPA were compared with doses calculated by GFR-estimating equations. Results Overall, the bedside Schwartz and Brandt equations did not precisely or accurately predict measured GFR (mGFR).
Introduction
A readily available method to assess glomerular filtration rate (GFR) in pediatric patients is important for dosing renally excreted pharmaceuticals and monitoring drug therapy. In children with cancer, accurate GFR results are essential to adjust the dosage of renally cleared medications (e.g., carboplatin) and to monitor for acute or chronic renal insufficiency. While accurate measurements of GFR using radioisotope, e.g., technetium-99m diethylenetriaminepentacetic acid ( 99m Tc-DTPA) or inulin clearance studies are available, they are not feasible for all institutions and are limited by resources, time, and cost constraints. Equations used to estimate GFR are of great importance for daily use when it is impractical to perform more cumbersome procedures.
Prior to creation of the Creatinine Standardization Program of the National Kidney Disease Education Program, estimation equations based on serum creatinine (SCr) measurements have been shown to overestimate GFR determined by isotope methods (iGFR) [1] [2] [3] . As a consequence, these firstgeneration equations lost their utility, and second-generation equations were developed using SCr measurements traceable to a method of calibrated isotope dilution mass spectrometry (IDMS) [1] . One commonly used pediatric GFR equations was developed by Schwartz and colleagues from the Chronic Kidney Disease in Children study and is often referred to as the bedside Schwartz equation [4] . It was developed for use in children with chronic kidney disease (CKD), and although useful in predicting renal function in a broader pediatric population, including in children with solid tumors [5] , other studies suggest it may not be useful for populations other than those for which it was developed [6, 7] .
An alternative second-generation equation was developed for children with solid tumors by Brandt et al. [8] . Children were studied prior to receiving chemotherapy (n = 111), and GFR was measured using serum iothalamate clearance. The resulting equation had an r 2 = 0.97 for predicting measured GFR (mGFR). Comparison of the original Schwartz equation in the same study group yielded an r 2 = 0.24. The study group later validated the Brandt equation in an additional cohort of 566 children (adjusted r 2 = 0.80) [9] . While the Brandt equation had reasonable precision and accuracy characteristics when evaluated in all patients, the authors noted that the equation was less reliable for GFR values >120 ml/min (regression r 2 = 0.23) compared with GFR < 120 ml/min (regression r 2 = 0.76). When normalized to 1.73 m 2 , this GFR cutpoint (120 ml/min) is similar to that proposed by the National Kidney Foundation (∼60 ml/min/1.73 m 2 ) and represents loss of half or more of the adult level of normal kidney function [10] . Investigators evaluating estimating equations compared with measured GFR often use this cutpoint as a method to determine performance characteristics.
Thus, objectives of this study were to determine the accuracy of the bedside Schwartz and Brandt equations for estimating mGFR determined by 99m Tc-DTPA clearance studies in our pediatric oncology population and to develop a new GFR estimation equation, which would be externally validated in a separate pediatric oncology cohort. In addition, we sought to evaluate the clinical utility of calculating carboplatin doses based on the estimated GFR (eGFR) from all equations and compare them with the dose calculated from the mGFR.
Patients and methods

Study population and GFR determination
This retrospective chart review of patients undergoing a 99m Tc-DTPA clearance study was conducted in two parts. First, eGFR values were calculated using the bedside Schwartz Tc-DTPA clearance studies conducted from September 2013 to June 2015 were used as an external validation cohort. This study and the waiver of informed consent were approved by the St. Jude Children's Research Hospital Institutional Review Board.
Patients were included in the study if they were <19 years of age with a successful 99m Tc-DTPA study as defined below. The radioisotope method utilized to measure GFR involved a single injection of 2 mCi/m 2 of 99m Tc-DTPA, followed by three timed samples at 1-, 2-, and 4-h postinjection [11] . Tc-DTPA clearance was determined by pharmacokinetic modeling using ADAPT II (University of Southern California, https://bmsr.usc. edu/software/adapt/). Patients were excluded if they had an unsuccessful 99m Tc-DTPA clearance study, which was defined as a volume of distribution outside the range of 5-10 L/m 2 , residuals >10% of the measured value, first blood sample drawn before hour 1, or results not consistent with patient clinical status as assessed by the clinical pharmacist. In addition, GFR measurements ≤10 ml/min/1.73m 2 or >200 ml/ min/1.73m 2 were excluded from analysis because they were characterized as extreme values [12] .
Estimation of GFR from bedside Schwartz and Brandt equations
Patient demographic and clinical covariates were extracted from the patient chart for each 99m Tc-DTPA clearance study. Information included height, weight, age, gender, SCr concentration, and blood urea nitrogen (BUN) values. SCr was measured using an IDMS-traceable enzymatic method (CREP prior to September 2013 and CREP2 after September 2013, Cobas). These data were used to calculate an eGFR at the time of each 99m Tc-DTPA clearance study using both the bedside Schwartz [4] and Brandt [8] equations, as follows:
where k is 0.95 for females and 1.05 for males. All eGFR calculations using the Brandt equation were normalized to a body surface area (BSA) of 1.73 m 2 to make them comparable with results of the 99m Tc-DTPA clearance studies and the eGFR determined using the bedside Schwartz equation.
Development of a new equation and external validation
After comparing the bedside Schwartz and Brandt equation to the mGFR, we found it necessary to develop a new equation to estimate GFR in our patient population. A subset of the 99m Tc-DTPA studies from January 2007 to August 2013 was used to develop two new equations (a more complex and a simplified version) by using univariate and multivariate linear regression. The overall performance of the equations and the performance in subgroups was evaluated for root mean square error (RMSE), predicted residual sum of squares (PRESS) statistics, number of parameters, and an adjusted r-squared. The equation was validated internally using the remainder of the studies from the January 2007 to August 2013 cohort and in an external cohort studied from September 2013 to June 2015. Performance characteristics (bias and accuracy) of the new equation in the external validation cohort were compared with those observed in the development cohort.
Calculation of carboplatin dose
To evaluate clinical utility of the new estimation equations compared with previously published equations, carboplatin dosages were calculated using a modified version of the Calvert equation, as follows [13, 14] :
where AUC is the area under the concentration-time curve defined as 6 mg/ml min, and GFR units are ml/min/m 2 . Measured GFR values from 99m Tc-DTPA clearance studies from January 2007 to August 2013 served as the reference with which to calculate the actual carboplatin dosage. Carboplatin dosages using the eGFR following the bedside Schwartz, Brandt, and the newly developed equations were all compared to the actual carboplatin dosage. Using the BSA for each patient, a carboplatin dose (mg) was also calculated for each individual.
Statistical analysis
As the focus of the analysis was to assess performance of the equations to estimate GFR, all DTPA clearance studies were treated as independent observations. Linear regressions and Bland-Altman plots were applied to characterize the correlation between 99m Tc-DTPA mGFR and eGFR for the bedside Schwartz, Brandt, and newly developed equations. Overall and subgroup-specific bias (defined as the difference between estimated and measured GFR values) and percent bias (defined as bias relative to mGFR on a percentage scale) were calculated for eGFR determined by the bedside Schwartz, Brandt, and the newly developed equations. Accuracy was assessed as percent of the estimates within 30% of the mGFR values (P 30 ), which takes into account higher errors at higher values and absolute values of the difference between mGFR and eGFR [15] . A receiver operator characteristic (ROC) curve analysis was performed to assess the performance of covariates in predicting dichotomized GFR (i.e., either ≤ 60 or >60 ml/min/1.73m 2 ). The actual and hypothetical carboplatin doses were compared by subtracting the dose determined from the 99m Tc-DTPA clearance study from the dose determined from the equation-estimated GFR, and the difference was expressed in terms of percentage error (%PE) and absolute percentage error (APE). The means of doses calculated using 99m Tc-DTPA and eGFR equations were compared by paired t tests, with effect sizes calculated as Cohen's d [16] . The %PEs between hypothetical and actual carboplatin doses are also shown as waterfall plots. Limits of underdosing (i.e., < −10% %PE) and overdosing (> 25% %PE) depicted in waterfall plots were chosen based upon suggested clinical relevance in adult studies [17] .
For all statistical analyses, a p value <0.05 was considered statistically significant. Statistical analyses were performed, and plots were generated using SAS (SAS Institute, Cary, NC, USA), Windows version 9.4.
Results
Estimation of GFR from bedside Schwartz and Brandt equations
From January 2007 to August 2013 August , 2036 Tc-DTPA clearance studies were performed in 1044 patients at St. Jude Children's Research Hospital. The demographics of these patients are described in Table 1 . A total of 1044 patients were studied, of whom 397 (38%) had a diagnosis of leukemia/ lymphoma or hematologic disorders, 421 (40%) solid tumors, 189 (18%) tumors of the central nervous system, and 37 (4%) a diagnosis of multiple primary diagnoses. As noted in Table 1 , the median 99m Tc-DTPA clearance for the study population was 114 ml/min/1.73 m 2 with extreme measurements excluded: one GFR measurement was ≤10 ml/min/1.73 m 2 (2 ml/min/1.73 m 2 ), and 40 observations from 36 patients had GFR values >200 ml/min/1.73 m 2 (∼2% of the total number of observations).
The bedside Schwartz and Brandt equations were used to estimate GFR and compared with mGFR from 99m Tc-DTPA clearance studies (Fig. 1a, b) and Bland-Altman analyses (Fig. 2a, b) . As depicted in the Bland-Altman analysis, both equations had a positive bias, but the overall range of difference as presented by ±2 standard deviations (SD) was less for the Brandt equation. The overall and group-specific bias and accuracy results for both equations are summarized in Table 2 presented as overall cohort (n = 2036 observations) subdivided by age groups, gender, and GFR (i.e., ≤ or >60 ml/ min/1.73m 2 based on adult values for kidney dysfunction [10] ). Although not listed in Table 2 , we also analyzed specific bias and accuracy results for both equations for both primary diagnoses subdividing the population into subgroups of hematological malignancies, brain tumors, and solid tumors. As noted in ESM Table 1 , study results were similar for all three types of malignancy. We also performed these analyses on index cases (distinct patients) and found similar results to analyses with all patients (ESM Table 2 ).
We had a particular interest in how well the equations performed in patients <24 months or with a GFR ≤ 60 ml/min/ 1.73m 2 . As shown in Table 2 , both the bedside Schwartz and Brandt equations performed poorly when estimating GFR in patients with reduced renal function defined as a GFR ≤ 60 ml/ min/1.73m 2 . Mean (±SD) percent bias for the bedside Schwartz equation was 71% (90%), and only 30% of calculated values were within 30% of the measured GFR values (P 30 ). Similarly, the Brandt equation had a mean (±SD) percent bias of 144% (93%), and the P 30 was only 4%. Conversely, bias and accuracy for both equations was much better for subgroup with GFR > 60 ml/min/1.73m 2 . For younger populations, the Brandt equation performed much better than the bedside Schwartz equation, with lower percent bias and greater P 30 values in all ages ≤24 months ( Table 2) .
Development of a new equation and external validation
The first step to develop our new equation was to randomly divide GFR values into an equation development group (two thirds) and equation validation group (one third). The covariates in this equation were age, gender, height/SCr, BUN and weight. Although it performed well in the development and validation groups, it had similar bias and P 30 characteristics to the bedside Schwartz and the Brandt equations (data not shown). Thus, we used the subgroup of patients with reduced renal function (GFR ≤ 60 ml/min/1.73m 2 ; n = 105 studies) to develop a new equation. Although this new equation performed well in that subgroup, it performed poorly in all other subgroups (data not shown). In this same analysis, we analyzed patient-specific characteristics that differed by GFR groups (i.e., GFR ≤ 60 and >60 ml/min/1.73m 2 ) and found that, not surprisingly, SCr and the ratio of height to SCr were statistically different between subgroups (p < 0.001). ROC analysis of the ratio of height/SCr showed excellent accuracy, with an area under the curve (AUC) of 0.90 predicting GFR > 60 ml/min/1.73m 2 . Accuracy was slightly improved when the combination of age, height, SCr, male gender, BUN, and height/SCr was used (AUC 0.92).
Thus, our next attempt to develop a new equation with the five covariates improved eGFR accuracy. We used all our studies with GFR values ≤60 ml/min/1.73m 2 (n = 105) and only one tenth with >60 ml/min/1.73m 2 (randomly selected; n = 194). The new equation was as follows: where HT is height in cm, SCr is serum creatinine in mg/dl, Age is in years, BUN is blood urea nitrogen in mg/dl, and Male is a categorical covariate, with yes = 1 and no = 0. The fivecovariate equation was then used to estimate mGFR in all , with a mean (±SD) percent bias of 37% (68%) and −5% (25%), respectively (Table 3) . Accuracy was better using this equation: P 30 for mGFR ≤ 60 ml/min/1.73m 2 and >60 ml/min/ 1.73m 2 of 61% and 81%, respectively. Furthermore, this five-covariate equation was much better than the bedside Schwartz at predicting GFR in patients <24 months but performed equally as well as the Brandt equation (Table 2  compared to Table 3 ). Overall, the five-covariate equation was much more accurate in all subgroups evaluated than were the bedside Schwartz or Brandt.
While the initial equation performed well in this patient cohort, it did require five patient covariates to estimate GFR. Though this would not be a problem for an electronic medical record, where the equation could be programmed into a dashboard setting, it could be challenging for a bedside application. Therefore, we sought to determine which of these covariates could be eliminated and still provide an equation that would be accurate at estimating GFR in pediatric oncology patients. ESM Fig. 1 shows a linear relationship between the ratio of height to SCr and mGFR. Therefore, a univariate analysis was performed using a simple linear regression model without an intercept, with the resulting equation:
where HT is height in cm and SCr is serum creatinine in mg/dl. This simplified equation was evaluated with all 2036 99m Tc-DTPA clearance studies, and bias, percent bias, and percent accuracy values are presented in Table 3 . While this equation has fewer covariates than the original, it performed similarly, making it a more practical equation to use at the bedside. Table 4 , the five-covariate and simplified equations had similar percent bias and P 30 in the overall population and the reduced renal function group (e.g., GFR ≤ 60 ml/min/1.73m 2 ), but both equations had greater bias and poorer accuracy (i.e., P 30 ) in the <12-month-old subgroup than in the equation development population (Table 3) .
Calculation of carboplatin dose
To further assess the clinical utility of our new equations, we calculated carboplatin dosages according to Eq. 3 using mGFR from 99m Tc-DTPA clearance studies compared to the carboplatin dose determined from the GFR estimating equations. The mean (SD) carboplatin dose using mGFR from 99m Tc-DTPA (n = 2036) and AUC of 6 mg/ml*min was 447 mg (250 mg). Mean (SD) carboplatin doses calculated using eGFR equations for the bedside Schwartz, Brandt, five-covariate, and simplified equations were 500 mg (250 mg), 528 mg (296 mg), 418 mg (224 mg), and 417 (208 mg), respectively.
Due to a large sample size (n = 2036), a statistically significant difference between the mean 99m Tc-DTPA calculated dose and the mean dose obtained using eGFR was found for all four equations (p < 0.05 each). However, the difference was small when the five-covariate (Cohen' Doses calculated using estimating formulas were compared to those obtained with the 99m Tc-DTPA approach using both percentage error (%PE) and absolute percentage error (APE). The five-covariate and simplified equations tended to slightly underdose patients (mean %PE −3.4% and −0.9%, respectively; Fig. 3 ), whereas the bedside Schwartz and Brandt equations tended to overdose patients (mean %PE 18.7% and 19.2%, respectively; Fig. 3 ). The five-covariate equation had the lowest APE (15.7%), followed by the simplified equation (mean APE 17.6%), and Brandt and bedside Schwartz equations had the highest mean APE (24.1% and 24.8%, respectively). Patients with an APE <10% were considered to have received an equivalent dose of carboplatin, and 40.8% and 38.1% of patients would have received equivalent dose of carboplatin using the five-covariate and simplified equations, respectively, compared with 29.8% of patients using bedside Schwartz and 31.5% the Brandt equation (Fig. 3) . We performed a similar analysis using just our external validation data set (n = 570 observations), and results were similar to those obtained with the development group (see ESM  Table 3 ).
Discussion
This study sought to first determine how well the bedside Schwartz and Brandt equations estimated mGFR by 99m Tc-DTPA clearance studies in children with cancer and second, to develop a new equation to accurately estimate GFR in pediatric patients, with a particular interest in children <24 months and patients with an mGFR ≤ 60 ml/min/1.73m 2 . Furthermore, the optimal equation would also accurately estimate GFR in patients with normal renal function. The results from this analysis showed that eGFR using the bedside Schwartz and the Brandt equations in pediatric oncology patients were biased and poorly accurate (Table 2) , confirming results from similar studies [18, 19] . Therefore, a new equation was developed using available patient covariates (Eq. 4) and further simplified (Eq. 5) to estimate GFR in our patient cohort. Both equations were more accurate at estimating GFR than the bedside Schwartz and Brandt equations (Table 3) , and were successfully externally validated in a separate pediatric oncology cohort (Table 4) . Furthermore, evaluating these equations in a clinical setting demonstrated the fivecovariate and simplified equations were better at matching the carboplatin dose using mGFR from 99m Tc-DTPA clearance studies than the bedside Schwartz and Brandt equations (Fig. 3) .
Andersen and colleagues compared the ability of GFR models to discriminate normal and reduced renal function in 119 children with nephrourological disorders [20] . The authors used 51 Cr-ethylenediaminetetraacetate (EDTA) as the index measure of GFR and variations on eight published GFR models. Different from our study, the authors only used GFR models to categorize renal function into normal, reduced, or needing a more precise test to be determined (or so called gray zone). They found that GFR models were, in general, adequate to screen for normal or reduced renal function, but only nine patients had GFR ≤ 60 ml/min/1.73 m 2 , limiting their ability to identify patients with severely impaired renal dysfunction.
Bernhardt and colleagues performed a retrospective evaluation of the performance of three equations (i.e., original Schwartz, bedside Schwartz, and Counahan-Barratt) to estimate GFR in 174 children with leukemia, lymphoma, or histiocytosis [18] . Similar to our study, they used 99m Tc-DTPA as the index measure of GFR and found that none of the three equations reliably estimated GFR. Using logistic regression analysis, they identified age and prior chemotherapy as predictors of observed estimation bias. However, they did not develop a new equation using this information.
A strength of our new equations, derived in a population of pediatric oncology patients, is that we had a large enough patient population to have a diversity of ages, diagnoses, and renal function. In both our model derivation and external validation data set, patients ranged in age from 1 month to 19 years. In addition, our population included patients with leukemia/lymphoma, other hematologic disorders, solid malignancies, and brain tumors. Approximately 5% (105 99m Tc- , which enhanced the likelihood the new equations would accurately estimate GFR for patients with renal dysfunction. In fact, our results clearly show that for the group of GFR ≤ 60 ml/min/1.73 m 2 , both our new equations (either the five-covariate or the simplified two-covariate) have less bias and better accuracy than either the bedside Schwartz or the Brandt equation. Specifically, accuracy as measured by the P 30 for the five-covariate, and the simplified equations was 60.95 compared with 29 for the Bedside Schwartz and only three for the Brandt. Thus, this represents at worst a twofold increase in accuracy and at best a 30-fold increase. Furthermore, this equation was developed using SCr measurements from an IDMS-traceable method, improving its clinical utility.
The five-covariate equation accurately estimated GFR compared with the mGFR by 99m Tc-DTPA clearance studies and may be the equation of choice by a clinician practicing in an environment with access to an electronic medical record (EMR), which could easily be coded to pull each patient characteristic to estimate GFR. However, a caveat is that patient covariates must be available within a reasonable time frame of each other to estimate GFR. The simplified equation with only two patient covariates (height and SCr) had slightly lower accuracy but performed similarly, improving its clinical utility.
Although the methods to measure SCr were similar between the bedside Schwartz and our new equations, it is well known that such methodological aspects may alter the coefficient of serum-based equations to estimate GFR. A mini review by Schwartz and Work [21] summarized several published GFR equations and demonstrated how covariates in each equation were similar (e.g., SCr, height), but that over time and presumably with changes in the methods of measuring SCr the coefficient has changed. Our equation differed from that of the bedside Schwartz by the coefficient only. However, this change in coefficient significantly increased eGFR accuracy (Tables 2 and 3) .
As with all retrospective studies, ours has limitations that must be considered when interpreting the results. Our patients all had various malignancies, so it is unknown whether the equations would perform well in other pediatric settings. Therefore, further validation in other pediatric cohorts is warranted. In addition, the generally lower SCr concentration in children makes the influence of a measurement error proportionally larger than the same magnitude error in an adult sample. However, this limitation applies to any equation estimating GFR that includes SCr.
In conclusion, this study developed a five-covariate equation and further simplified this equation to one with two covariates to estimate GFR in pediatric oncology patients, showing better accuracy than the bedside Schwartz and Brandt equations. We recommend using the simplified new equation on a daily basis for estimating GFR in pediatric oncology patients due to its accuracy and ease of use.
